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Summary
Background Deﬁ nitive chemoradiotherapy (CRT) is an alternative to surgery for the curative treatment of oesophageal 
carcinoma. The SCOPE1 trial aimed to investigate the addition of cetuximab to cisplatin and ﬂ uoropyrimidine-based 
deﬁ nitive CRT in patients with localised oesophageal squamous-cell cancer and adenocarcinomas to assess activity, 
safety, and feasibility of use.
Methods In this multicentre, randomised, open-label, phase 2/3 trial, we recruited patients aged 18 years and older 
from UK radiotherapy centres who had non-metastatic, histologically conﬁ rmed carcinoma of the oesophagus 
(adenocarcinoma, squamous-cell, or undiﬀ erentiated; WHO status 0–1; stage I–III disease) and been selected to 
receive deﬁ nitive CRT. Patients were randomly assigned (1:1) via a central computerised system using stratiﬁ ed 
minimisation (with an 80:20 random element) to receive CRT alone or CRT with cetuximab (400 mg/m² on day 1 
followed by 250 mg/m² weekly), stratiﬁ ed by recruiting hospital, primary reason for not having surgery, tumour 
histology, and tumour stage. CRT consisted of cisplatin 60 mg/m² (day 1) and capecitabine 625 mg/m² twice daily 
(days 1–21) for four cycles; cycles three and four were given concurrently with 50 Gy in 25 fractions of radiotherapy. 
The primary endpoint was the proportion of patients who were treatment failure free at week 24 for the phase 2 trial 
and overall survival for the phase 3 trial, both measured from randomisation. We analysed data by intention to treat. 
This trial is an International Standard Randomised Controlled Trial, number 47718479.
Findings 258 patients (129 assigned to each treatment group) from 36 UK centres were recruited between Feb 7, 
2008, and Feb 22, 2012. Recruitment was stopped without continuation to phase 3 because the trial met criteria for 
futility, but we continued to follow-up recruited patients until all had reached at least 24-week follow-up (median 
follow-up of patients who survived was 16·8 months [IQR 11·2–24·5]). Fewer patients were treatment failure free 
at 24 weeks in the CRT plus cetuximab group (79 of 119 patients [66·4%, 90% CI 58·6–73·6]) than in the CRT only 
group (93 of 121 patients [76·9%, 69·7–83·0]). The CRT plus cetuximab group also had shorter median overall 
survival (22·1 months [95% CI 15·1–24·5] vs 25·4 months [20·5–37·9]; adjusted HR 1·53 [95% CI 1·03–2·27]; 
p=0·035). Patients who received CRT plus cetuximab had more non-haematological grade 3 or 4 toxicities (102 
[79%] of 129 patients vs 81 [63%] of 129 patients; p=0·004). The most common grade 3 or 4 toxicities were low 
white blood cell count (14 [11%] in the CRT plus cetuximab group vs 21 [16%] in the CRT only group), low absolute 
neutrophil count (15 [12%] vs 24 [19%]), fatigue (26 [20%] vs 25 [19%]), and dysphagia (35 [27%] vs 37 [29%]).
Interpretation The addition of cetuximab to standard chemotherapy and radiotherapy cannot be recommended for 
patients with oesophageal cancer suitable for deﬁ nitive CRT.
Funding Cancer Research UK.
Introduction
In the UK, oesophageal cancer is the  sixth most 
common cause of cancer death, accounting for around 
5% of all cancer deaths.1 Worldwide, oesophageal 
cancer is the eighth most common cancer—an 
estimated 482 300 new cases and 406 800 deaths 
occurred in 2008—and it has the ﬁ fth highest mortality 
rate of all tumour sites.2 The incidence of oesophageal 
adenocarcinomas predom inantly aﬀ ecting the lower 
oesophagus and gastro-oesophageal junction has 
increased substantially in recent decades, especially in 
Europe and the USA.2 The incidence of squamous-cell 
carcinoma is stable or falling in the UK, but is much 
more prevalent in southern and east Africa and east 
Asia.
Surgery has been the cornerstone of curative treatment 
for this disease for the past 50 years, but is only appropriate 
for 10–20% of the patient population, and despite 
improvements in patient selection, perioperative care, and 
adjuvant treatment, less than 25% will survive 5 years 
after treatment3,4 and those who relapse within 2 years of 
surgery never regain their former quality of life.5
Chemoradiotherapy when given as deﬁ nitive treat-
ment is more eﬀ ective than radiotherapy6 or chemo-
therapy alone.7 In the UK, this treatment is usually 
oﬀ ered to patients who are unsuitable for surgery. 
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Unsuitability for surgery might be due to the extent of 
disease precluding the likelihood of a curative resection, 
or because the patient is physiologically not ﬁ t for 
surgery because of comorbidities or poor performance 
status. Less often, patients or clinicians will opt for this 
strategy.8 Increasingly, deﬁ nitive chemoradiotherapy is 
being considered as a standard of care in patients with 
oesophageal squamous-cell carcinoma, because 
evidence suggests that outcomes are similar to those of 
surgical treatment.3,6,9 By contrast, for adenocarcinomas, 
evi dence to support the use of deﬁ nitive 
chemoradiotherapy is less strong and is restricted to 
studies of chemo radiotherapy in patients who are 
unsuitable for surgery.
Concurrent chemoradiotherapy regimens have been 
based on cisplatin and ﬂ uorouracil. Both drugs have 
good single-agent activity in oesophageal malignant 
disease and are two of the best radiosensitisers in tumour 
models.10,11 The regimen used most frequently in the UK 
consists of conformal external beam radio therapy (50 Gy 
in 25 fractions for 5 weeks) with two cycles of cisplatin 
and ﬂ uorouracil given concurrently, with or without a 
further two cycles of the same chemo therapy, given in a 
neoadjuvant phase. This neoadjuvant phase, as well as 
delivering additional systemic therapy, allows time for 
careful radiotherapy planning, frequently improves 
patients’ dysphagia, and debulks the tumour before 
radiotherapy. Capecitabine has been shown to be as 
eﬀ ective as ﬂ uorouracil in locally advanced and meta-
static oesophagogastric cancer.7 Encouraging outcomes 
with deﬁ nitive chemoradiotherapy regimens were 
reported in single-centre series,8,12 but whether the 
ﬁ ndings could be replicated in a prospective, multicentre 
trial was unclear.
Although deﬁ nitive chemoradiotherapy in patients 
with a poor outlook can lead to useful long-term disease 
control, most patients still succumb to the disease. The 
pattern of treatment failure diﬀ ers from that after 
surgery, with a higher rate of locoregional recurrence.6,8,9,12 
Improvements to both the systemic and locoregional 
components of this treatment strategy are therefore 
urgently needed.
EGFR is overexpressed in up to 55% of oesophago-
gastric cancers and is associated with poor prognosis.13 
Cetuximab, a monoclonal EGFR antagonist, improved 
outcomes when given in combination with chemo therapy 
in other tumours—eg, advanced colorectal adeno-
carcinomas14 and squamous-cell head and neck cancer.15 
More importantly, preclinical studies have shown that 
cetuximab can overcome an important mechanism of 
radioresistance,16 and results of a phase 3 trial by Bonner 
and colleagues17 in squamous-cell carcinoma of the head 
and neck showed that cetuximab in combination with 
radiotherapy can improve local control and overall survival 
compared with radiotherapy alone. We therefore 
postulated that cetuximab in combination with con-
ventional deﬁ nitive chemoradiotherapy might improve 
local control, quality of life, and overall survival in patients 
with localised oesophageal squamous-cell cancer and 
adenocarcinomas. On behalf of the UK National Cancer 
Research Institute (NCRI) Upper GI Clinical Studies 
Group we designed the SCOPE1 trial (Study of 
Chemoradiotherapy in OesoPhageal cancer with Erbitux) 
to test this hypothesis. 
Methods
Study design and patients
In this multicentre, randomised, open-label, parallel, 
two-arm, phase 2/3 trial, we recruited patients from 
radiotherapy centres in the UK who had the following 
key eligibility criteria (for full inclusion and exclusion 
criteria see appendix): non-metastatic, histologically 
conﬁ rmed carcinoma of the oesophagus (adenocar-
cinoma, squamous-cell, or undiﬀ erentiated carcinoma) 
or gastro-oesophageal junction (Siewert type 1 or 2 with 
<2 cm extension into the stomach); selected for deﬁ nitive 
chemoradiotherapy by a designated multidisciplinary 
team; aged 18 years or older; WHO performance status 
0 or 1; stage I–III disease (TNM stage 6); and disease 
length of less than 10 cm deﬁ ned by endoscopic 
ultrasound. Patients with M1a or M1b were not eligible 
for this study. The protocol for the study has been 
published elsewhere18 and the trial was coordinated by 
the Wales Cancer Trials Unit (WCTU).
Patients were required to have staging investigations 
that consisted of endoscopic ultrasound and contrast-
enhanced spiral CT scan of the thorax and abdomen. 
¹⁸F-ﬂ uorodeoxyglucose CT-PET scan was optional. In 
patients in whom endoscopic ultrasound was not possible 
because of advanced malignant oesophageal stricturing, 
patients were staged with CT with or without CT-PET. 
Patients were physiologically assessed to identify those 
with eligible lung function (forced expiratory volume in 1 s 
>1·0), cardiac function (left ventricular ejection fraction 
>40% on echocardiogram or multigated acquisition scan), 
renal function (EDTA glomerular ﬁ ltration rate [GFR] 
>40 mL/min, or estimated by Cockcroft-Gault formula to 
be >60 mL/min), liver function (serum bilirubin 
≤1·5×upper limit of normal [ULN], aspartate amino-
transferase to alanine aminotransferase ratio ≤2·5×ULN, 
alkaline phosphatase ≤3×ULN) and haematological 
assessment (haemoglobin >100 g/L, white blood cells 
>3×10⁹/L, absolute neutrophil count [ANC] >1·5×10⁹/L, 
platelet count >100×10⁹/L). All treatment and assessments 
were done in UK radiotherapy centres.
All patients had to provide written informed consent 
before registration and the trial protocol was approved 
by the UK Medicines and Healthcare products 
Regulatory Agency and a multicentre research ethics 
committee. The SCOPE1 trial was sponsored by 
Velindre NHS Trust and coordinated by the WCTU at 
Cardiﬀ  University. Cancer Research UK’s Clinical Trials 
Awards and Advisory Committee (CTAAC) approved the 
trial design.
See Online for appendix
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Randomisation and masking
Eligible patients were randomly assigned (1:1) to chemo-
radiotherapy with cetuximab (CRT plus cetuximab) or 
chemoradiotherapy without cetuximab (CRT only) by 
stratiﬁ ed minimisation with a random element (80:20). 
Randomisation was stratiﬁ ed by recruiting hospital, 
primary reason for not having surgery, tumour histology, 
and tumour stage. To conceal the sequence until inter-
ventions were assigned, research nurses (who recruited 
the patients) telephoned the WCTU where the random 
allocation sequence was generated by a trial or data 
manager interacting with a computerised system. The 
study had an open-label design. Participants, those 
administering the interventions, and those assessing the 
outcomes were aware of which treatment had been 
allocated.
Procedures
Both study groups received the same chemotherapy, 
which consisted of four 3-weekly cycles of cisplatin 
(60 mg/m² intravenously on day 1) and capecitabine 
(625 mg/m² orally twice daily from day 1 to day 21); cycles 
one and two were given as neoadjuvant treatment. Cycles 
three and four were given concurrently with radiotherapy. 
This regimen is the most frequently used regimen in the 
UK. Patients randomly assigned to the CRT plus 
cetuximab group also received intravenous cetuximab 
400 mg/m² on day 1 of chemotherapy and 250 mg/m² 
weekly for the 12 weeks of treatment. If patients were 
unable to swallow capecitabine, investi gators could use a 
protracted intravenous infusion of ﬂ uorouracil at a rate 
of 225 mg/m² per day from day 1 to day 21 of each cycle. 
Full details of protocol treatment and dose reductions are 
detailed in the trial protocol.
Dose modiﬁ cation for haematological toxicity was based 
on a full blood counts taken within the 3 days before the 
start of each cycle of chemotherapy. Full-dose 
chemotherapy was given if ANC was 1×10⁹/L or higher 
and platelet count was 75×10⁹/L or higher. For ANC 
0·5×10⁹/L to less than 1×10⁹/L or a platelet count 50×10⁹/L 
to less than 75×10⁹/L, chemotherapy was stopped until 
recovery of counts and restarted with a 25% dose 
reduction of cisplatin and capecitabine. For ANC below 
0·5×10⁹/L or platelet count below 50×10⁹/L, chemotherapy 
was restarted with a 50% dose reduction. Renal 
modiﬁ cation was based on GFR at baseline and before 
day 1 of chemotherapy. Patients received full-dose 
chemotherapy if their GFR was 50 mL/min or higher. 
Cisplatin was given at a 75% dose reduction to patients 
with GFR of 40–50 mL/min, and replaced by carboplatin 
(at a concentration to achieve an area under the con-
centration–time curve of 5) if GFR was below 40 mL/min. 
Capecitabine was given at a 75% dose reduction if GFR 
was below 50 mL/min, a 50% dose reduction if GFR was 
below 40 mL/min, and omitted if GFR was below 
30 mL/min. For other non-haematological toxicities of 
grade 2 or higher, chemotherapy was withheld until 
resolution to grade 0–1. Further chemotherapy was 
omitted for grade 4 toxicity, and given at 75% and 50% 
dose reductions after the ﬁ rst and second occurrences of 
grade 3 toxicity. For grade 2 toxicity, subsequent 
chemotherapy was given at 100%, 75%, and 50% dose 
reductions after the ﬁ rst, second, and third occurrences of 
toxicity. For cetuximab-induced skin toxicity, cetuximab 
was continued along with topical emollient and antibiotics 
if the patient had a grade 1 acneiform rash. Oral antibiotics 
were mandated for grade 3 rash and recommended for 
grade 2 rash. Sequential dose reduction of cetuximab to 
200 mg/m² and 150 mg/m² was advised for second and 
third occurrences of grade 3 skin rash, respectively; it was 
permanently discontinued after a fourth appearance.
The radiotherapy protocol and planning guidance 
document mandated the use of intravenous contrast CT 
simulation with minimum 3-mm CT slices. 50 Gy in 
25 fractions, prescribed according to recommendations 
by the Inter national Commission on Radiation Units and 
Measure ments (ICRU-50/62), was delivered Monday to 
Friday as a three-dimensional (3D) conformally planned 
single-phase treatment, usually with four radiotherapy 
ﬁ elds to achieve the following normal organ dose 
constraints: less than 30% of the heart volume to receive 
at least 40 Gy, less than 25% of the lung volume to receive 
at least 20 Gy, and a maximum dose in the spinal cord of 
less than 40 Gy. Gross tumour volume was deﬁ ned by 
diagnostic CT scan, endoscopy and endoscopic 
ultrasound, and PET scan information (when available). 
The clinical target volume was cal culated by adding 2 cm 
manually along the oesophagus superiorly–inferiorly 
and 1 cm radially. The ﬁ nal planning target volume was 
then created by adding 1 cm superiorly–inferiorly and 
0·5 cm radially to the clinical target volume. Elective 
nodal irradiation was not done.
All potential principal investigators and radiotherapy 
centres received a CD-ROM containing the detailed 
radiotherapy protocol, a radio therapy planning 
guidance document, and example planning cases. All 
principal investigators had to outline a benchmark case 
For the trial protocol see http://
www.wctu.org.uk/trial.
php?trial=scope1
Figure 1: Trial proﬁ le
129 were assigned to
chemoradiotherapy plus
cetuximab
258 were randomly assigned
540 patients were assessed for 
eligibility
282 excluded 
         213 did not meet inclusion 
                  criteria
           66 refused
              3 other reasons
129 assigned to 
chemoradiotherapy only
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and radiotherapy centres then planned the same case, 
which had to pass central review before patient 
recruitment.19 On-trial radiotherapy trials quality 
assurance (RTTQA) consisted of all principal investi-
gators’ ﬁ rst plans, 10% of all subsequent plans, and 
trial-speciﬁ c planning assessment forms for each 
patient submitted for central review that outlined and 
assessed the 3D dose distribution before treatment. 
SCOPE1 RTTQA was coordinated by the NCRI RTTQA 
centre in Cardiﬀ , UK.
During treatment, patients were reviewed within the 
3 days before day 1 of each cycle of chemotherapy during 
the neoadjuvant phase and weekly during the deﬁ nitive 
chemoradiotherapy phase. Assessment at each review 
consisted of medical examination and assessment of 
WHO performance status, dysphagia score, and toxicity 
according to the US National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (CTCAE version 
3.0). Capecitabine compliance was assessed by counting 
the number of tablets at each visit. Blood tests including 
full blood count and biochemical proﬁ le were done at 
each clinic visit. Blood and biopsy samples were obtained 
at both baseline and week 24, but the processing of these 
samples is still in progress, and correlations with treat-
ment response will be the subject of a future paper.
Follow-up was at 24 weeks, then every 3 months after 
that during the ﬁ rst year, every 4 months during the 
second year, and yearly thereafter for a minimum of 
5 years from randomisation. All patients had an 
endoscopic assessment, biopsy, and CT scan 12 weeks 
after com pletion of deﬁ nitive chemoradiotherapy (at 
week 24). No further CT scan was mandated, and further 
investigations (endoscopy or CT scan) were done 
according to patient symptoms. The choice of second-
line treatment, in cluding salvage surgery in the case of 
locoregional recurrence, was left to the discretion of the 
treating clinician. Patients completed validated quality-
of-life questionnaires (European Organisation for 
Research and Treatment of Cancer [EORTC] QLQ-C3020 
and QLQ-OES18,21 dermatology life-quality index, and 
EQ-5D) and a health-care resource utilisation log at 
baseline and weeks 7, 13, 24, and 52, and yearly thereafter 
(to 5 years after randomisation). We postulated that 
scores for physical and role function, fatigue, dysphagia, 
and eating restrictions would be better over time in the 
CRT plus cetuximab group than in the CRT only group. 
Missing data were managed according to the standard 
guidelines associated with each questionnaire.
The primary endpoint of the phase 2 trial was the 
proportion of patients who were treatment failure free at 
24 weeks (12 weeks after completion of treatment). 
A patient was deemed treatment failure free if they were 
still alive with no evidence of residual malignancy in the 
endoscopic biopsy sample, and no evidence of disease 
progression outside the radiotherapy ﬁ eld on CT scan. 
Secondary endpoints were toxicity, quality of life, health 
economics, progression-free survival (overall, local, and 
distant), treatment compliance, and feasibility of 
recruitment. Local progression-free survival was deﬁ ned 
as the time to progression within the radiotherapy ﬁ eld 
(with or without metastatic disease) or death by any cause. 
Distant progression-free survival was deﬁ ned as time to 
progression with metastases or death by any cause.
Statistical analysis
With the addition of cetuximab to the intervention group, 
we felt that a treatment-failure-free rate of less than 60% 
CRT plus cetuximab 
(n=129)
CRT only (n=129)
Age (years)
Median 66·9 66·6
Range (IQR) 44·9–84·1 (61·3–73·7) 35·7–81·9 (60·2–72·3)
Aged ≥70 years 50 (39%) 48 (37%)
Sex
Male 71 (55%) 74 (57%)
Female 58 (45%) 55 (43%)
WHO performance status
0 61 (47%) 70 (54%)
1 68 (53%) 59 (46%)
Reason for no surgery
Local extent of disease 60 (47%) 62 (48%)
Patient choice 48 (37%) 49 (38%)
Comorbidity/poor 
performance status
21 (16%) 18 (14%)
PET used in staging
Yes 109 (84%) 112 (87%)
No 17 (13%) 16 (12%)
Missing data 3 (2%) 1 (<1%)
Site of predominant tumour
Upper 15 (12%) 12 (9%)
Middle 56 (43%) 58 (45%)
Lower 54 (42%) 58 (45%)
Missing data 4 (3%) 1 (<1%)
Tumour type
Adenocarcinoma 33 (26%) 32 (25%)
Squamous cell 92 (71%) 96 (74%)
Undiﬀ erentiated 4 (3%) 1 (<1%)
Stage
I 4 (3%) 4 (3%)
IIa 36 (28%) 36 (28%)
IIb 12 (9%) 11 (9%)
III 77 (60%) 78 (60%)
Total EUS disease length (cm)
Mean (SD) 5·6 (2·7) 5·6 (2·4)
Missing data 37 (29%) 28 (22%)
Time of start of treatment from randomisation (days)
Median 5 4
Range (IQR) 0–34 (2–7) 0–22 (2–7)
Data are number (%) unless otherwise speciﬁ ed. CRT=chemoradiotherapy. 
EUS=endoscopic ultrasound.
Table 1: Baseline characteristics of randomly assigned patients 
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at week 24 would not be suﬃ  ciently large enough to 
warrant further investigation in a phase 3 setting, but 
that a rate of 75% or higher would warrant further 
investigation. Using a Fleming’s single-stage design 
(p1=0·60; p2=0·75; α=0·05; 90% power; 10% loss to 
follow up), we needed to recruit 90 patients in the CRT 
plus cetuximab group (180 patients overall). Subject to 
the independent data monitoring committee’s review of 
the phase 2 analysis, the study would proceed to phase 3 
with a primary endpoint of overall survival from date of 
randomisation. However, we were to continue recruiting 
patients until the phase 2 trial was analysed. For the 
phase 3 trial, we needed to recruit 420 patients 
(269 events) to detect an improvement in 2-year overall 
survival from 35% to 47·5% (hazard ratio [HR] 0·71) in 
patients assigned to CRT plus cetuximab, with 80% 
power at 5% signiﬁ cance.
Data were analysed with the Stata 11 statistical package 
according to intention to treat. We used the Clopper-
Pearson exact binomial method to calculate 90% CIs for 
the phase 2 primary endpoint. Analyses of the proportion 
of patients who were treatment failure free were done 
using the number of patients who died or progressed 
before 24 weeks, or those with a valid 24-week assess ment, 
as the denominator. A valid 24-week assessment was 
deﬁ ned as a follow-up visit between 20 and 28 weeks after 
randomisation at which a CT scan or endoscopic biopsy 
was done. We calculated survival from date of 
randomisation to when an event occurred (ie, pro gression 
CRT plus 
cetuximab 
(n=129)
CRT only 
(n=129)
Cisplatin
Completed cycles 1–4 at full dose 73 (57%) 69 (53%)
Completed cycles 1–4 at full or reduced dose 99 (77%) 116 (90%)
Stopped before cycle 4 due to patient choice 4 (13%)* 1 (8%)†
Stopped before cycle 4 due to toxicity/illness 26 (87%)* 12 (92%)†
Capecitabine
Completed cycles 1–4 at full dose 32 (25%) 44 (34%)
Completed cycles 1–4 at full or reduced dose 89 (69%) 110 (85%)
Stopped before cycle 4 due to patient choice 4 (10%)‡ 0§
Stopped before cycle 4 due to toxicity/illness 36 (90%)‡ 19 (100%)§
Switched to ﬂ uorouracil before cycle 4 7 (5%) 7 (5%)
Number of cycles of cetuximab completed at full or reduced dose
0 1 (<1%) NA
1 9 (7%) NA
2 16 (12%) NA
3 14 (11%) NA
4 89 (69%) NA
Radiotherapy
Full protocol dose 100 (78%) 116 (90%)
Dose reduction 4 (3%) 3 (2%)
No radiotherapy given 25 (19%) 10 (8%)
CRT=chemoradiotherapy. NA=not applicable. *Out of 30 patients who stopped 
cisplatin before cycle 4. †Out of 13 patients who stopped cisplatin before cycle 4. 
‡Out of 40 patients who stopped capecitabine before cycle 4. §Out of 19 patients 
who stopped capecitabine before cycle 4. 
Table 2: Treatment compliance in randomly assigned patients
CRT plus cetuximab (n=129) CRT only (n=129)
Haematological 27 (21%) 36 (28%)
Haemoglobin 3 (2%) 3 (2%)
WBC 14 (11%) 21 (16%)
ANC 15 (12%) 24 (19%)
Platelets 11 (9%) 6 (5%)
Lymphocytes 5 (4%) 3 (2%)
Non-haematological 102 (79%) 81 (63%)
Cardiac disorders 8 (6%) 2 (2%)
Cardiac ischaemia/infarction 3 (2%) 1 (<1%)
Other 5 (4%) 1 (<1%)
Dermatological 28 (22%) 5 (4%)
Acne 9 (7%) 0
Hand-foot syndrome 7 (5%) 4 (3%)
Rash 14 (11%) 0
Other 9 (7%) 1 (<1%)
Metabolic/laboratory 31 (24%) 14 (11%)
Hypomagnesia 9 (7%) 2 (2%)
Hypokalaemia 9 (7%) 7 (5%)
Hypophosphataemia 6 (5%) 1 (<1%)
Hyponatraemia 2 (2%) 1 (<1%)
Bilirubin 2 (2%) 0
Hyperuricaemia 2 (2%) 0
Other 13 (10%) 6 (5%)
Pulmonary 8 (6%) 4 (3%)
Dyspnoea 8 (6%) 3 (2%)
Other 2 (2%) 1 (<1%)
Constitutional symptoms 27 (21%) 26 (20%)
Fatigue 26 (20%) 25 (19%)
Weight loss 3 (2%) 3 (2%)
Gastrointestinal 55 (43%) 57 (44%)
Diarrhoea 12 (9%) 8 (6%)
Dysphagia 35 (27%) 37 (29%)
Stomatitis 4 (3%) 2 (2%)
Nausea 6 (5%) 11 (9%)
Oesophagitis 3 (2%) 7 (5%)
Vomiting 7 (5%) 11 (9%)
Anorexia 12 (9%) 13 (10%)
Other 7 (5%) 9 (7%)
Infection 8 (6%) 9 (7%)
Febrile neutropenia 3 (2%) 3 (2%)
Infection with normal ANC 5 (4%) 6 (5%)
Neurological 5 (4%) 5 (4%)
Vascular 14 (11%) 13 (10%)
Thrombosis/thrombus/embolism 14 (11%) 12 (9%)
Other 2 (2%) 1 (<1%)
Other 12 (9%) 10 (8%)
All randomly assigned patients received at least one dose of treatment. CRT=chemoradiotherapy. WBC=white blood 
cell. ANC=absolute neutrophil count. CTCAE=Common Terminology Criteria for Adverse Events.
Table 3: CTCAE grade 3 or 4 toxicity in patients during treatment (weeks 1 to 12)
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or any death for progression-free survival, and any death 
for overall survival). Patients who were event free were 
censored at the time they were last assessed. We estimated 
event time distributions with the Kaplan-Meier method 
and compared overall survival and progression-free 
survival with an unadjusted log-rank test and HRs from 
Cox regression, both unadjusted and adjusted for 
randomisation strati ﬁ cation factors (we tested the 
proportional hazards assumption with Cox-Snell residuals 
and Schoenfeld’s global test). We included all randomly 
assigned patients who met the eligibility criteria in the 
analysis of their allocated group. We assessed toxicity by 
comparing proportions of haematological and non-
haematological toxicities during chemoradiotherapy with 
Pearson’s χ² tests in all patients who received at least one 
dose of treatment. We compared quality-of-life score 
diﬀ erences with Wilcoxon rank sum tests. We prespeciﬁ ed 
all the analyses that we have presented below. Detailed 
quality-of-life analyses, health economic analyses, and 
correl ation of outcomes with radiotherapy treatment 
delivery will be presented in future reports.
This trial is an International Standard Randomised 
Controlled Trial, number 47718479.
Role of funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The statistician (CH) had full access to all the 
data and the corresponding author (TC) and statistician 
(CH) had ﬁ nal responsibility for the decision to submit for 
publication. Merck Serono provided the cetuximab free of 
charge but had no role in study design, data collection, 
data analysis, data interpretation or writing of the report.
Results
258 patients were recruited from 36 of the 56 radiotherapy 
centres in the UK between Feb 7, 2008, and Feb 22, 2012 
(ﬁ gure 1). In February, 2012, the independent data 
monitoring committee undertook a preplanned analysis 
of the ﬁ rst 180 patients recruited who had completed 
24 weeks of follow up, and recommended stopping 
recruitment because the trial had met predetermined 
criteria for futility. When making this decision, they also 
took into account toxicity, treatment compliance, and 
overall survival, and recommended completion of treat-
ment and follow-up of all recruited patients. The data 
presented here are those from all 258 patients (129 pa-
tients allocated to each treatment group) who were 
recruited up until the independent data monitoring 
committee’s decision, analysed after the last patient had 
undergone assessment at week 24. The median length of 
follow-up for patients who had survived by the time of 
analysis was 16·8 months (IQR 11·2–24·5).
Patient and tumour baseline characteristics were well 
balanced between groups (table 1). Patients who were 
assigned to receive CRT plus cetuximab were less likely 
to com plete standard protocol treatment than were those 
assigned to the CRT only group (table 2). The com pliance 
diﬀ erence between groups was signiﬁ cant for completion 
(at full or reduced dose) of four planned cycles of cisplatin 
(p=0·005), completion of four cycles of capecitabine 
(p=0·002), and delivery of any radiotherapy (104 [81%] of 
129 patients in the CRT plus cetuximab group vs 119 [92%] 
of 129 patients in the CRT only group; p=0·006; table 2). 
The number of patients whose cisplatin dose was 
reduced (or stopped) was similar in each group (56 [43%] 
in the CRT plus cetuximab group vs 60 (47%) in the CRT 
only group). The number of patients whose capecitabine 
dose was reduced was higher in the CRT plus cetuximab 
group than in the CRT only group (97 [75%] vs 85 [66%]). 
More patients in the CRT plus cetuximab group stopped 
both cisplatin and capecitabine treatment early because 
CRT plus cetuximab 
(n=129)
CRT only (n=129)
Lost to follow-up before 24 weeks 10 (8%) 8 (6%)
Too ill for assessments/withdrew/moved away 8 (80%) 6 (75%)
Invalid 24 week assessment (too early/late) 2 (20%) 2 (25%)
Died before 24 weeks 17 (13%) 8 (6%)
Oesophageal cancer 11 (65%) 4 (50%)
Treatment related 3 (18%) 0 
Other 3 (18%) 4 (50%)
Valid 24-week assessment 102 (79%) 113 (88%)
Failure at 24-week assessment 23 (23%) 20 (18%)
By biopsy 20 (87%) 10 (50%)
By endoscopy 0 3 (15%)
By CT scan 3 (13%) 7 (35%)
Failure free at 24 weeks 79 (66%) 93 (77%)
Alive and without progression at last follow-up 49 (62%) 58 (62%)
Progressed at last follow-up 17 (22%) 23 (25%)
Local 7 (41%) 10 (43%)
Metastatic 2 (12%) 6 (26%)
Both 8 (47%) 7 (30%)
Died of any cause before progression 13 (16%) 12 (13%)
Oesophageal cancer 13 (100%) 8 (67%)
Pulmonary embolism 0 1 (8%)
Stroke 0 1 (8%)
Cardiac failure/heart disease 0 1 (8%)
Liver disease 0 1 (8%)
Post-trial treatments up to 12 months after randomisation*
Patients with completed treatment follow-up data 88 (68%) 97 (75%)
Surgery 0 3 (3%)
Palliative chemotherapy 7 (8%) 2 (2%)
Radiotherapy 1 (1%) 2 (2%)
Endoscopic intervention
Oesophageal stent 2 (2%) 2 (2%)
Oesophageal dilatation 1 (1%) 6 (6%)
Oesophageal laser therapy 1 (1%) 0 
Stent plus dilation 1 (1%) 1 (1%)
CRT=chemoradiotherapy. *No patients started more than one of the treatments listed here. 
Table 4: Failure-free rate at 24 weeks, and subsequent pattern of treatment failure and treatments given
Articles
www.thelancet.com/oncology   Vol 14   June 2013 633
of toxicity or illness than did those in the CRT only group 
(cisplatin stopped, 26 [20%] vs 12 [9%]; capecitabine 
stopped, 36 [28%] vs 19 [15%]).
All CTCAE grade 3 or 4 toxicities (including serious 
adverse reactions and suspected unexpected serious 
adverse reactions) reported during treatment are shown 
in table 3. Patients who received CRT plus cetuximab had 
more non-haematological toxicity (p=0·004). These 
toxicities were mainly dermatological, biochemical 
(metabolic or laboratory tests), and cardiac disorders 
(table 3).
The proportion of patients who were treatment failure 
free at 24 weeks was lower in the CRT plus cetuximab 
group than in the CRT only group (79 of 119 patients 
[66·4%, 90% CI 58·6–73·6] vs 93 of 121 patients [76·9%, 
69·7–83·0]). Patients who were failure free at 24 weeks 
had signiﬁ cantly better median overall survival than did 
those who were not failure free (8·3 months [95% CI 
6·7–12·5] vs 26·7 months [24·5–42·7]). Of those patients 
who were failure free at 24 weeks, 107 (62%) of 172 were 
still alive without progression at the end of the study 
follow-up, whereas 40 (23%) were alive with progression 
and 25 (15%) had died. Of patients who died before 
24 weeks, more were recorded as having oesophageal 
cancer as the cause of death in the CRT plus cetuximab 
group than in the CRT only group (table 4). Three 
treatment-related deaths occurred in the CRT plus 
cetuximab group (one stroke, one multiorgan failure, 
one pulmonary embolism). 29 patients are known to 
have had further treatment during the 12 months after 
randomisation (table 4).
Overall survival was signiﬁ cantly worse in the CRT 
plus cetuximab group than in the CRT only group 
(unadjusted HR 1·45 [95% CI 1·01–2·09], log-rank 
p=0·043; adjusted HR 1·53 [1·03–2·27], p=0·035; 
ﬁ gure 2). Median overall survival was 22·1 months 
(95% CI 15·1–24·5) in the CRT plus cetuximab group 
and 25·4 months (20·5–37·9) in the CRT only group. 
This pattern was consistent across randomisation strati-
ﬁ cation characteristics (ﬁ gure 3). 2-year overall sur vival 
was also lower in the CRT plus cetuximab group than in 
the CRT only group (41·3% [95% CI 30·9–51·4] vs 56·0% 
[45·1–65·6]), as well as median progression-free survival, 
but not signiﬁ cantly so (15·9 months [95% CI 11·0–21·1] 
vs 21·6 months [16·2–27·8]; un adjusted HR 1·26 [95% CI 
0·90–1·77], log-rank p=0·17; adjusted HR 1·29 
[0·89–1·85], p=0·18), median distant progression-free 
survival (18·4 months [13·3–23·2] vs 25·4 months 
[18·4–29·3]), and local progression-free survival 
(15·9 months [11·0–21·1] vs 21·6 [16·2–27·8]).
Figures 4 and 5 show the results of the quality-of-life 
analysis. At baseline, 246 (95%) patients completed the 
QLQ-C30 and 240 (93%) patients completed QLQ-OES18. 
A completion rate of 69% or above was maintained at 
week 13 (184 [71%] completed QLQ-C30 and 178 [69%] 
completed QLQ-OES18); the major reason for loss to 
follow-up was attrition. The change in the fol lowing 
scores from baseline to week 13 did not diﬀ er signiﬁ cantly 
between groups: physical function (z=−1·139, p=0·25; 
n=177), role function (z=−1·207,p=0·23; n=177), fatigue 
(z=0·520, p=0·60; n=177), dysphagia (z=1·395, p=0·16; 
n=167), and eating restrictions (z=0·031, p=0·98; n=167). 
In each case, n represents the number of patients who 
had completed questionnaires at both baseline and week 
13. Full quality-of-life data will be reported elsewhere.
Discussion
As the result of a preplanned assessment, the inde-
pendent data monitoring committee reported that the 
primary endpoint of the phase 2 stage of the SCOPE1 
trial had not been met and recommended closing the 
Figure 2: Kaplan-Meier curves of overall survival by treatment group
CRT=chemoradiotherapy.
0
25
50
75
100
O
ve
ra
ll 
su
rv
iv
al
 (%
)
129 114 87 56 31 12 8 3 2CRT only
129 106 70 45 25 16 12 4 1CRT plus cetuximab
Number at risk
0 6 12 18 24 30 36 42 48
Months from randomisation
CRT plus cetuximab
CRT only
Figure 3: Hazard ratio plots for overall survival, by baseline characteristics
Survival data are median number of months (95% CI) in all patients. Positions of squares show hazard ratio of 
death in the CRT plus cetuximab group compared with death in the CRT only group; the area of each square 
represents the amount of information (ie, the number of patients) in each category. Lines show 95% CIs. 
CRT=chemoradiotherapy. NC=not calculable because of small numbers of patients.
Reason for no surgery
Local extent of disease
Patient choice
Comorbidity/poor performance status
Tumour type
Adenocarcinoma
Squamous cell
Other
Stage
I
II
III
n
122
97
39
65
188
5
8
95
155
Deaths
56
45
18
34
83
2
1
36
82
Survival (months)
22·2 (16·1−25·4)
24·7 (20·0−30·3)
23·2 (12·8−NC)
19·7 (14·7−25·8)
24·0 (20·5−27·8)
··                
··               
30·3 (19·7−NC)
20·7 (16·9−24·7)
0·5 1·0 2·0 4·0
Favours CRT
+ cetuximab
Favours CRT only
Articles
634 www.thelancet.com/oncology   Vol 14   June 2013
trial to further recruitment and not proceeding to 
phase 3. The addition of cetuximab to chemoradiotherapy 
resulted in more toxicity, less protocol treatment being 
delivered, and worse overall survival than with chemo-
radiotherapy alone, although quality of life was not 
reduced compared with chemoradiotherapy alone. This 
eﬀ ect on overall survival was consistent across pre-
determined subgroups—ie, histological subtype, tumour 
stage, and the reason for not undergoing surgery. There-
fore, the addition of cetuximab to standard deﬁ nitive 
chemoradiotherapy cannot be recommended.
The outcome of SCOPE1 is consistent with recent 
results from other randomised trials comparing the 
addition of anti-EGFR therapy to standard treatment 
across several tumour sites (panel). In the REAL3 study,23 
patients with advanced oesophagogastric cancer received 
epirubicin, oxaliplatin, and capecitabine with or without 
panitumumab. Patients who received the monoclonal 
antibody received a lower protocol dose of capecitabine 
and oxaliplatin. Despite this prespeciﬁ ed dose modi-
ﬁ cation, patients in the chemotherapy plus panitumumab 
group received a lower median number of cycles than did 
the control group (ﬁ ve vs six), a lower median dose 
intensity of capecitabine, and had worse overall survival 
(8·8 months vs 11·3 months; HR 1·37; p=0·01). The 
Radiation Therapy Oncology Group (RTOG) 0522 trial24 
sought to build on the results of Bonner and colleagues’ 
study17 by adding cetuximab to cisplatin or ﬂ uoro-
pyrimidine-based chemoradiation in a similar patient 
population with squamous-cell head and neck cancer. 
Once again, no beneﬁ t was reported in terms of 
progression-free survival or overall survival, although an 
increased rate of mucositis was noted in the patients 
treated with cetuximab.24 In the COIN trial,25 which 
randomly assigned 2445 patients with metastatic colo-
rectal cancer to oxaliplatin–ﬂ uoropyrimidine (ﬂ uoro-
uracil or capecitabine) chemotherapy with or without 
cetuximab, a higher than anticipated incidence of grade 3 
or 4 diarrhoea (30%) in the experimental group resulted 
in a dose modiﬁ cation of capecitabine during the course 
of the trial. No overall improvement in survival was 
reported in patients randomly assigned to receive 
cetuximab. The EXPAND study26 also showed no beneﬁ t 
from adding cetuximab to ﬁ rst-line chemotherapy in 
advanced gastric cancer. In the SCOPE1 trial, the REAL3 
trial,23 and for most patients in the COIN trial,25 a 
capecitabine backbone was used and the resultant 
reduction in doses of standard therapy might have 
contributed to the worse outcome in the cetuximab 
groups of these trials. As seen in the REAL3 study,23 
patients receiving cetuximab had a lower rate of 
haematological toxicity, possibly as a result of the lower 
chemotherapy dose intensity delivered.
Perhaps more importantly—with respect to this study 
of an investigational drug in deﬁ nitive treatment of 
oesophageal cancer—was the eﬀ ect on the dose of 
radiotherapy delivered. More than twice the number of 
patients in the CRT plus cetuximab group than in the 
CRT only group did not receive any radiotherapy (25 vs 
10). As systemic therapies move from palliative, through 
to adjuvant, to deﬁ nitive treatment protocols, evidence-
based treatment regimens should be vigilantly protected, 
especially if such treatments are intensiﬁ ed.
Another explanation for these results, independent of 
dose intensity, is the possible occurrence of a negative 
interaction between cetuximab and chemoradiotherapy. 
The proinﬂ ammatory and antitumour proliferative 
eﬀ ects of cetuximab have been proposed as the cause of 
Figure 4: Physical functioning score from QLQ-C30 in each treatment group at ﬁ ve timepoints over 52 weeks
The number of patients shows the amount who completed QLQ-C30 at each timepoint. A higher score indicates 
better function. Bars show 95% CI. QLQ-C30=European Organisation for Research and Treatment of Cancer’s 
Quality of Life Questionnaire C30.
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reduced eﬃ  cacy in combination with chemoradiation in 
rectal cancer.27 A similar interaction between oxaliplatin 
and cetuximab has been proposed, speciﬁ cally that 
cetuximab might protect against free-radical damage by 
platinum drugs,28 and again could explain the negative 
outcome in this and other studies.25,29 Despite this 
reduction in survival, however, and increased toxicity, we 
did not record an eﬀ ect on quality of life according to 
standard EORTC generic and disease-speciﬁ c measures.
The EGFR pathway seems to be important in the 
carcinogenesis of oesophagogastric malignancy30 and a 
beneﬁ t of anti-EGFR therapy has been shown in head 
and neck cancer in combination with radiotherapy17 and 
in advanced disease.15 The negative outcome in this study 
therefore seems to be a result of tumour-speciﬁ c 
interactions and biology that are not fully understood, or 
overlapping toxicities that preclude the delivery of 
eﬀ ective standard treatment.
An understanding of why the overall survival in this 
trial was better than anticipated will be important; 2-year 
overall survival was predicted to be 35% in the CRT only 
group in the phase 3 design. Despite the fact that most 
patients had stage III disease, 38% of patients were older 
than 70 years, and 15% of patients had comorbidities that 
precluded surgery, the 2-year overall survival in all 
patients was 49%, and was 56% in those receiving CRT 
only. Indeed, the overall survival in the CRT only group 
exceeded that which was hoped to be seen by the addition 
of cetuximab and was better than that seen in the US and 
UK studies exploring the role of the addition of 
neoadjuvant chemotherapy to surgery.3 Although one of 
the lead authors in our investigation (TC) has previously 
published encouraging out comes of single centre, 
retrospective series,8,12 whether these outcomes could be 
reproduced in a multicentre, prospective study was 
unclear. Before this trial, concerns had been raised about 
the quality of radiotherapy delivered in multicentre 
UK studies of radiotherapy in upper gastrointestinal 
cancers.31 Such studies did not have detailed radiotherapy 
treatment protocols and had near-absent radiotherapy 
quality assurance. Standard practice throughout the UK 
varied substantially before this study;32 therefore, we 
made RTTQA an important aspect of the study design. 
We developed a detailed protocol mandating the use of 
endoscopic ultrasound and intravenous contrast to aid 
localisation of target volume and used a single-phase 
conformal treatment plan.33 This plan, together with a 
comprehensive radiotherapy planning protocol and test 
cases, was sent to all principal investigators and 
radiotherapy centres before patients were recruited.19 We 
propose that this protocol, together with the on-trial 
quality assurance programme providing a positive 
dialogue between recruiting units and the RTTQA 
central team, was a crucial component to the successful 
outcomes seen in the CRT only group. The beneﬁ t of 
RTTQA has been reported in other studies.34 To the best 
of our know ledge, this trial is the largest prospective 
study with a comprehensive assessment of quality of life 
with disease and cancer-speciﬁ c questionnaires in 
patients under going deﬁ nitive chemoradiotherapy. 
Scores achieved in patients surviving for 2 years in our 
study are compatible with that achieved by surgical-based 
treatments.5
Other factors that could have contributed to improved 
outcomes in this study are patient selection and organ-
isation of cancer services throughout the UK. Although 
not mandated, 86% of patients had a PET scan before 
starting radiotherapy. PET has been shown to both 
exclude patients with metastatic disease not otherwise 
seen with endoscopic ultrasound and CT scan35 and be 
useful in radiotherapy planning.36 Substantial recon-
ﬁ guration of oesophagogastric cancer treatment ser vices 
in the UK has also taken place in the past decade.37,38 
Although the changes have mainly been in centralisation 
of surgical services, they have led to the development of 
regional specialist multidisciplinary teams, which has 
Panel: Research in context
Systematic review
We identiﬁ ed a systematic review22 on combined modality 
radiotherapy and chemotherapy in non-surgical 
management of localised carcinoma of the oesophagus that 
searched Medline (1996–2001), Cancerlit (1983–2001), 
Cochrane Library databases (2001), and abstracts published 
in the American Society of Clinical Oncology and the 
American Society for Therapeutic Radiology and Oncology 
(1999–2001) for articles published in any language. Search 
terms included “esophageal neoplasms” with the 
subheadings “drug therapy”, “radiotherapy”, or “therapy”. The 
review reported the beneﬁ ts of chemoradiotherapy (CRT) 
compared with radiotherapy alone; however, it also showed 
that most patients still relapse with locoregional or 
metastatic disease. We also identiﬁ ed studies that reported 
that cetuximab, a monoclonal EGFR antagonist, improved 
outcomes when given in combination with: chemotherapy in 
advanced colorectal adenocarcinomas and squamous-cell 
head and neck cancer; and radiotherapy in squamous-cell 
head and neck cancer.  
Interpretation
Cetuximab should not be given in addition to chemoradiation 
in an unselected patient population. The results of our study 
do, however, support the use of chemoradiation alone as a 
standard of care in patients with non-metastatic 
squamous-cell carcinoma of the oesophagus and in patients 
with non-metastatic adenocarcinoma who are not suitable 
for surgery. Indeed, the outcomes of this study would support 
the increased use of this treatment in patients who have a 
higher risk of failure of surgical treatment, either due to the 
existence of comorbidities or where surgical excision is likely 
to be incomplete. A randomised trial to compare surgical and 
radiotherapy-based treatments in patients with oesophageal 
cancer with a better outlook is warranted.
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undoubtedly added rigour to treatment decisions and 
patient selection. The 2012 annual report of the UK 
National Oesophago-gastric Cancer Audit38 has showed 
an improvement in outcomes for patients undergoing 
surgery, with 45% of patients surviving for 3 years. Both 
of these areas have scope for further development, 
namely the incorporation of CT-PET more directly into 
radiotherapy planning and assessment of caseload, with 
outcomes in specialist non-surgical services.
How can we build further on the encouraging clinical 
outcomes reported in the CRT only group of this study? 
Clearly, as patients continue to relapse with both meta-
static and locoregional disease, systemic and local com-
ponents of this treatment strategy need to be improved 
and intensiﬁ ed. Systemic treatments should either have 
independent activity in oesophageal cancer or have 
synergistic eﬀ ects with radiotherapy in the form of 
radiosensitisation or overcoming mechanisms of radio-
resistance. However, newer therapies need to be carefully 
integrated so as not to compromise the dose intensity 
of standard chemoradiotherapy. High concentrations of 
tumoral ERCC1 might predict platinum resistance,39 
which might be overcome with alternative chemotherapy 
such as taxane-containing regimens. The overexpression 
of HER2 (also known as ERBB2) predicts whether the 
addition of trastuzumab will beneﬁ t patients with 
advanced oesophagogastric cancer.40 The safety and 
eﬃ  cacy of anti-HER2 therapy should be tested as part of 
chemoradiotherapy treatment in this patient population.
A radiotherapy dose–response eﬀ ect in patients with 
oesophageal cancer has been known for some time.41 
However, a study designed to test the beneﬁ t of a 
higher radiation dose given concurrently with cisplatin 
and ﬂ uoropyrimidine chemotherapy was prematurely 
stopped for futility as a result of an excess of treatment-
related deaths occurring in the high-dose treatment group.9 
We believe, however, that by using newer radiotherapy 
techniques, such as intensity-modulated and image-
guided radiotherapy, we can now safely deliver a higher 
dose of radiation to a highly conformal target volume 
within the context of a high-quality RTTQA programme.
This trial was a phase 2/3 study that ended on 
completion of phase 2. The study did not reach the full 
sample size needed for the comparison of overall survival 
powered for under the phase 3 design. However, we do 
plan to follow-up patients for 5 years. Additionally, 
although the study stratiﬁ ed patients according to 
tumour histology, it was not powered to assess with 
certainty the beneﬁ t of cetuximab in each of the two 
main histological variants of this disease.
This trial has not shown that the addition of cetuximab 
to standard deﬁ nitive chemoradiotherapy beneﬁ ts pa-
tients with locally advanced oesophageal cancer. In fact, 
the addition of cetuximab increased toxicity, reduced 
delivery of all components of standard chemoradio-
therapy, and was associated with a signiﬁ cant reduction 
in overall survival. The use of cetuximab in combination 
with cisplatin and capecitabine-based deﬁ nitive chemo-
radiotherapy in patients with localised oesophageal 
cancer cannot be recommended. However, the very 
encouraging outcomes seen with deﬁ nitive chemoradio-
therapy alone should provide an excellent platform to test 
more targeted therapeutic approaches, incorporating 
biomarker-driven systemic therapies and newer radio-
therapy technologies to safely intensify treatment, in-
cluding increases to radiotherapy doses.
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